Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells

D. L. White; L. N. Eadie; V. A. Saunders; D. K. Hiwase; T. P. Hughes

doi:10.1038/leu.2012.295

Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells

D. L. White, L. N. Eadie, V. A. Saunders, D. K. Hiwase, T. P. Hughes

Blood Cancer Program

Research output: Contribution to journal › Letter › peer-review

8 Citations (Scopus)

Original language	English
Pages (from-to)	1201-1204
Number of pages	4
Journal	Leukemia
Volume	27
Issue number	5
DOIs	https://doi.org/10.1038/leu.2012.295
Publication status	Published or Issued - May 2013

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/leu.2012.295

Cite this

@article{91ff5874494744eb9ec02d41a68607d0,

title = "Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells",

author = "White, \{D. L.\} and Eadie, \{L. N.\} and Saunders, \{V. A.\} and Hiwase, \{D. K.\} and Hughes, \{T. P.\}",

note = "Funding Information: DLW and TPH have received research funding from Novartis Oncology. TPH has received Honoraria from Novartis Oncology. The rest of the authors declare no conflict of interest. Funding Information: This work was supported by a Translational Grant from the Leukemia Lymphoma Society of USA. Imatinib and nilotinib along with their 14-C-labeled variants were kindly provided by Novartis (Basel). Laura N Eadie is a PhD Scholar funded by the Leukemia Foundation of Australia.",

year = "2013",

month = may,

doi = "10.1038/leu.2012.295",

language = "English",

volume = "27",

pages = "1201--1204",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "5",

}

TY - JOUR

T1 - Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells

AU - White, D. L.

AU - Eadie, L. N.

AU - Saunders, V. A.

AU - Hiwase, D. K.

AU - Hughes, T. P.

N1 - Funding Information: DLW and TPH have received research funding from Novartis Oncology. TPH has received Honoraria from Novartis Oncology. The rest of the authors declare no conflict of interest. Funding Information: This work was supported by a Translational Grant from the Leukemia Lymphoma Society of USA. Imatinib and nilotinib along with their 14-C-labeled variants were kindly provided by Novartis (Basel). Laura N Eadie is a PhD Scholar funded by the Leukemia Foundation of Australia.

PY - 2013/5

Y1 - 2013/5

UR - http://www.scopus.com/inward/record.url?scp=84877622305&partnerID=8YFLogxK

U2 - 10.1038/leu.2012.295

DO - 10.1038/leu.2012.295

M3 - Letter

C2 - 23164803

AN - SCOPUS:84877622305

SN - 0887-6924

VL - 27

SP - 1201

EP - 1204

JO - Leukemia

JF - Leukemia

IS - 5

ER -

Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this